Gilead names Michael Boyd VP of government affairs, policy
Boyd has worked at AbbVie, Pfizer, and Schering-Plough.
Regulatory
4 expert takes on what the midterms mean for pharma
MM&M asked experts to predict what the next two years could hold for pharma- and healthcare-related legislation.
These 5 companies have the most at stake if drug prices are based on international averages
The Trump administration has proposed basing Medicare Part B drug prices on what other countries pay.
Trump orders drug companies to disclose list prices in DTC ads. Will it actually happen?
PhRMA pushed back on the HHS plan for disclosing drug prices in ads, putting itself in Trump’s Twitter crosshairs, but experts say flaws in the plan could impede its rollout anyway.
FDA looks for ideal way to convey risk info in drug ads
The FDA wants to know what’s the ideal context for risk info. Some experts assert that the question misses the point.
PCMA appoints AdvaMed veteran J.C. Scott as CEO
Outgoing Pharmaceutical Care Management Association chief executive Mark Merritt is stepping down after 15 years.
With a nod from the FDA, Teva enters white-hot migraine market
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
Bigelow to succeed Kamp as head of Coalition for Healthcare Communication
John Kamp has served as the group’s executive director for 16 years.
Pfizer petitions FDA for biosimilar communications guidelines
The pharma company urged the government agency to take action on “misleading” communications about biosimilars.
Congress puts big price tag on innovation in pharma
It has become expensive to develop drugs — especially for specific mutations and small patient populations. But instead of helping pharma adapt, Congress is making innovation more costly.
Want to read more?
Please login or register first to view this content.
